Patents Assigned to Inserm
  • Patent number: 11512294
    Abstract: The disclosure pertains to the field of molecular means capable of binding to, and preferably of chelating, cGMP, appropriate for use in vitro or in vivo and preferably capable of targeting specific cellular compartments. The polypeptides of the disclosure comprise a chimeric construction derived from the N terminus part of PKG-I? and PKG-I?, and the two cGMP binding sites of the wild type PKG.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: November 29, 2022
    Assignees: SORBAOONE UNIVERSITE, CENTRE NATIONAL DE LA RECHARCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET LA RECHERCHE MEDICALE (INSERM)
    Inventors: Xavier Nicol, Oriol Ros Torres
  • Patent number: 11511016
    Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: November 29, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Cité
    Inventors: Catherine Le Visage, Didier Letourneur
  • Patent number: 11510896
    Abstract: The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: November 29, 2022
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Manuel Rosa-Calatrava, Olivier Terrier, Anaïs Proust, Vincent Moules
  • Patent number: 11510936
    Abstract: In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent memory tasks and LTP. Inventors clearly provide evidence for multiple roles of Pyk2 in spine morphology and postsynaptic structure. Thus, the inventors used direct overexpression of PYK2 by AAV-mediated gene transfer into the brain of Huntington's and Alzheimer's mouse models and found that overexpression of PYK2 in these 2 models improves synaptic properties and spine density deficits which is also accompanied by a rescue of spatial memory. Accordingly it was demonstrated that PYK2 may restore cognitive functions in neurodegenerative diseases. Thus the present invention relates to methods and pharmaceutical compositions for the treatment of neurodegenerative disease.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: November 29, 2022
    Assignees: INSERM, SORBONNE UNIVERSITE, UNIVERSITAT DE BARCELONA
    Inventors: Jean-Antoine Girault, Albert Giralt, Veronica Ines Brito, Silvia Gines
  • Patent number: 11508261
    Abstract: The invention relates to a method for obtaining a numerical model, the numerical model associating at least one objective measurement to a subjective sensation, the method comprising the steps of: a) imaging the at least one area of the brain by using unfocused waves produced by a transcranial ultrasound probe (20), to obtain at least one acquired image of the activity of the area, b) evaluating a physical quantity representative of the activity of the at least one area based on the acquired images, to obtain at least one objective measurement, c) obtaining from the subject at least one numerical value representative of a subjective sensation, and d) determining the numerical model by using the obtained objective measurement and the obtained numerical value.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: November 22, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Centre National de la recherche scientifique, Université Pierre et Marie Curie, Université Paris Diderot, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Thomas Deffieux, Mickaël Tanter, Jean-Luc Gennisson, Zsolt Lenkei, Mathieu Pernot
  • Patent number: 11504424
    Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 22, 2022
    Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE LAVAL
    Inventors: Manuel Rosa-Calatrava, Guy Boivin, Julia Dubois, Mario Andres Pizzorno, Olivier Terrier, Marie-Eve Hamelin, Marie-Helene Cavanagh
  • Patent number: 11504094
    Abstract: An apparatus and a method for contrast-enhanced ultrasound (CEUS) including use of a fluid dynamics model for the analysis of dynamic contrast-enhanced ultrasound (DCEUS).
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 22, 2022
    Assignees: (INSERM) INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE TOURS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BORDEAUX, INSTITUT POLYTECHNIQUE DE BORDEAUX (IPB)
    Inventors: Baudouin Denis de Senneville, Franck Perrotin, Jean-Michel Escoffre, Ayache Bouakaz
  • Publication number: 20220361896
    Abstract: A medical device for penetrating a bone structure including a processing unit having a transfer function that associates an electrical conductivity value S with a depth value d, wherein the processing unit is configured to detect a threshold selected from amongst an absolute threshold, a relative threshold and a critical gradient, and to emit a warning signal and/or control signal responsive to detection of the threshold.
    Type: Application
    Filed: May 2, 2022
    Publication date: November 17, 2022
    Applicants: SpineGuard, Sorbonne Universite, Centre National de la Recherche Scientifique - CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Stephane BETTE, Jimmy DA SILVA, Thibault CHANDANSON, Guillaume MOREL, Maurice BOURLION
  • Publication number: 20220362179
    Abstract: The present invention relates to compounds and compositions comprising said compounds, for use in the prevention and/or treatment of non-alcoholic fatty liver disease (NAFLD), in particular hepatic steatosis or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: October 23, 2020
    Publication date: November 17, 2022
    Applicants: SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jérémie GAUTHERON, Vlad RATZIU
  • Patent number: 11499154
    Abstract: The present invention concerns the use of antisense oligonucleotides (AON) capable of inhibiting expression of dynamin 2, advantageously human dynamin 2, for use in the treatment of Charcot-Marie-Tooth disease (CMT) and centronuclear myopathies (CNM).
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: November 15, 2022
    Assignees: GENETHON, UNIVERSITE D'EVRY-VAL-D'ESSONNE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventor: Ana Maria Buj Bello
  • Publication number: 20220356520
    Abstract: The present invention relates to a digital multiplex method for detecting and/or quantifying multiple target biomolecules in a sample, said biomolecules being selected from DNA, RNA, and proteins. The present invention further relates to different applications of the digital multiplex method and to a kit.
    Type: Application
    Filed: May 27, 2020
    Publication date: November 10, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, PARIS SCIENCES ET LETTRES, UNIVERSITE DE PARIS
    Inventors: Guillaume GINES, Yannick RONDELEZ, Thomas JET, Valérie TALY
  • Patent number: 11491117
    Abstract: The disclosure pertains to a compound of formula (I), one of its pharmaceutically acceptable salts, or a composition comprising thereof, for use in the prevention or treatment of glucose intolerance related conditions, insulin deficit related conditions, nonalcoholic fatty liver disease and/or obesity.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 8, 2022
    Assignees: SORBONNE UNIVERSITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, KYOTO UNIVERSITY
    Inventors: Dominique Gauguier, Fumihiko Matsuda, François Brial
  • Publication number: 20220348587
    Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 3, 2022
    Applicants: CENTRE LEON BERARD, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Toufic RENNO, Isabelle COSTE-INVERNIZZI, Stéphane GIRAUD, Serge LEBECQUE
  • Patent number: 11484537
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 1, 2022
    Assignees: AELIS FARMA, INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUX
    Inventors: Pier Vincenzo Piazza, Sandy Fabre, Mathilde Metna, Stéphanie Monlezun, Arnau Busquet-Garcia, Daniela Cota, Giovanni Marsicano, Jean-Michel Revest, Monique Vallée
  • Patent number: 11484577
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 1, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
  • Patent number: 11484529
    Abstract: The present invention relates to desmethylanethole trithione (AOX) and derivatives thereof, especially derivatives of formula (I), for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin,
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: November 1, 2022
    Assignees: OP2 Drugs, Centre Hospitalier Universitaire de Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux
    Inventors: Philippe Diolez, Frédéric Marin, Olivier Petitjean
  • Patent number: 11484569
    Abstract: The invention concerns a Reg3? polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3? lectin into the gastrointestinal tract (GIT) lumen of hReg3?-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3? exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3?-transgenic mice resist better to DSS-induced colitis after antibiotherapy.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: November 1, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), UNIVERSITÉ PARIS-SUD
    Inventors: Joël Dore, Jamila Faivre, Nicolas Moniaux, Christian Brechot, Marion Darnaud
  • Publication number: 20220341912
    Abstract: The invention is related to a method for measuring the variability of the red blood cells deformability of an individual by determining the amount of red blood cells having a tank-treading motion in a population of red blood cells from a tested blood sample of said individual, and comparing the amount to a reference amount. The determination of the amount of red blood cells having a tank-treading motion is carried out using a visualisation means such as a brightfield microscope.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 27, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE, AIX-MARSEILLE UNIVERSITE
    Inventors: Annie VIALLAT, Emmanuele HELFER, Catherine BADENS, Scott ATWELL, Anne CHARRIER
  • Patent number: 11478486
    Abstract: The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: October 25, 2022
    Assignees: INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventors: Céline Gongora, Diego Tosi
  • Patent number: 11479817
    Abstract: The present invention relates to a method for discriminating an operationally tolerant (TOL) subject from a non-operationally tolerant (STA) subject, comprising the following steps: i) establishing a composite score of tolerance (cSoT) with the expression levels of six genes in a biological sample obtained from said subject and two clinical parameters; wherein said six genes are ID3, AKR1C3, CD40, CTLA4, TCL1A and MZB1, and wherein said cSoT is established by the following formula: cSoT = ? i n ? = ? i × Exprs + ? test ? ? time × age test ? ? time + ? trans ? ? time × age trans ? ? time + intercept - scaling ? ? coefficient ii) comparing this cSoT with a predetermined reference value; and iii) concluding that the subject is TOL when the cSoT is higher than the predetermined reference value or concluding that the subject is STA when the cSoT is lower than the predetermined reference value.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: October 25, 2022
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université de Nantes, Centre Hospitalier Universitaire de Nantes, Centre National de la Recherche Scientifique
    Inventors: Richard Danger, Sophie Brouard, Magali Giral, Gérard Ramstein